The Role of TNFα and Sphingolipid Signaling in Cardiac Hypoxia: Evidence that Cardiomyocytes Release TNFα and Sphingosine by Amy L. Cavalli et al.
The Role of TNFα and Sphingolipid Signaling in Cardiac Hypoxia: 
Evidence that Cardiomyocytes Release TNFα and Sphingosine 
Amy L. Cavalli, Joseph A. Ligutti, Nicole M. Gellings, Ernesto Castro, M. Trevor 
Page, Robert E. Klepper, Philip T. Palade
(1), Wm. T. McNutt and Roger A. Sab-
badini
(2) 
Heart Institute and Department of Biology, San Diego State University, San Diego, 
(1) Department of Physiology and Biophysics, University of Texas Medical Branch 
at Galveston, Galveston and (2) Medlyte, Inc. 
Abstract 
Sphingosine (SPH) is a naturally occurring signaling molecule thought to be responsible for 
the negative inotropic and cardiotoxic effects of the pro-inflammatory cytokine, TNFα. When 
subjected to hypoxia and acidosis, Langendorff perfused adult rabbit hearts generate SPH, and 
isolated adult rat cardiomyocytes released TNFα and SPH into the cell-conditioned media un-
der hypoxic conditions before hypoxia-induced cell permeabilization associated with necrosis. 
Cardiomyocyte SPH production in response to hypoxia was blocked by TNFRII:Fc which in-
terferes with TNFα binding to its membrane-bound receptor, suggesting that hypoxia-
triggered SPH production was TNFα dependent. Extracellular SPH was rapidly converted 
almost exclusively to S1P by an active sphingosine kinase present in blood components, as 
seen  in vitro and in Langendorff-perfused rat hearts. These results indicate that cardiac-
derived TNFα and its sphingolipid mediator, SPH, may be important extracellular signals in 
the heart that contribute to the pathogenesis of cardiac ischemia. 
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Sphingolipids are primary structural components of cell 
membranes that also serve as cellular signaling and regu-
latory molecules [1, 2]. Ceramide (CER), sphingosine 
(SPH) and sphingosine-1-phosphate (S1P) have been 
most widely studied and have recently been appreciated 
for their roles in the cardiovascular system [see review, 
[3)]. Recent work suggests that SPH may mediate the 
negative inotropic effects of the pro-inflammatory cyto-
kine TNFα [4-7] through direct actions on the ryanodine 
receptor [8] and the L-type channel [6, 9, 10]. Moreover, 
SPH is a very potent inducer of apoptosis in both neonatal 
and adult rat cardiomyocytes [11-13]. 
Since the sphingomyelin signal transduction pathway is 
activated very early during cardiac hypoxia [14, 15], car-
diac tissue-derived tumor necrosis factor alpha (TNFα) 
might mediate ischemia/hypoxia induced sphingolipid 
production. The ischemic myocardium produces TNFα 
[15-19], which stimulates the sphingomyelinase activity 
of adult cardiomyocytes [5] leading to increased intracel-
lular SPH in cardiomyocytes [5, 6, 11, 15]. Provided with 
the proper stimulus (e.g., LPS, cell stretch), cardiomyo-
cytes themselves produce substantial TNFα and secrete 
the cytokine into the extracellular medium [20, 21], 
where it may act on TNFα receptors expressed on car-
diomyocytes [4, 22] in an autocrine/paracrine fashion. 
We have recently reported that serum levels of SPH are 
elevated in an experimental model of heart failure [13] 
and that serum SPH and S1P are elevated in patients with 
severe coronary artery disease [23]. 
The present study was undertaken to determine if 
TNFα and sphingolipids are produced and released by 
hypoxic cardiomyocytes. We report that TNFα is re-
leased from cardiomyocytes and activates the sphingo-
myelin signal transduction system, resulting in the re-
lease of substantial amounts of SPH into the extracellu-
lar medium as well. Platelets take up extracellular SPH 
and convert it to S1P, which has pleotropic effects on 
cardiac tissue. We propose novel roles for TNFα, SPH 
and S1P as extracellular signaling molecules that par-
ticipate in the heart’s response to ischemic stress. 
Methods 
Adult cardiomyocyte preparation 
All procedures involving experimental animals were 
performed in accordance with institutional and NIH 
guidelines for the ethical treatment of animals. Primary 
cultures of adult rat cardiomyocytes were prepared es-
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sentially as described previously [11], except for the use 
of pyrogen-free collagenase (Liberase blendzyme, 
Roche, Indianapolis, IN) for digestion of the rat hearts. 
Adult cardiomyocytes were cultured for 3 hours in 
10% FCS/DMEM until treatment at densities of 35,000 
cells per plate (35mm culture dish). Prior to treatment, 
cells were allowed to equilibrate in warm (37
oC) Ty-
rode’s solution for 1 hour [10]. The purity of the adult 
cardiomyocyte preparation was assessed as 86 ± 1% rod 
shaped cells after 3 hours in culture (data from 8 sepa-
rate cell preparations). 
Hypoxia cell culture 
Cardiomyocytes were cultured on plastic dishes 
placed in a humidified modular incubator chamber (ICN 
Biomedicals, Aurora, OH) pressurized to 0.04-0.05 psi 
by the particular gas mixture used in the treatment in 
experiments similar to those published by others [14] 
that demonstrated early activation of sphingomyelinase 
in cultured cardiomyocytes exposed to mild hypoxia. 
Warm (37
oC) Tyrode’s solution containing 0.2mM 
BSA, ampicillin (50mg/mL), kanamycin (100mg/mL) 
and fungizone (20µg/mL) was gassed for 15 minutes 
with 95%N2/5%CO2 prior to cell treatment. Control 
(normoxia) cells were treated the same except with 
95%O2/5%CO2 and incubated in a standard incubator. 
At the end of each incubation period, the cell-
conditioned media was aspirated and saved for analysis. 
Cell viability assays 
Cardiomyocytes were stained with Hoechst bisben-
zimide and propidium iodide (Sigma, St. Louis, MO) to 
access the viability of the cells as previously described 
[20]. Single cell microgel electrophoresis (the comet 
assay) was used to quantify the percent apoptotic cells 
as previously reported [11, 24]. 
Langendorff perfusion of rabbit hearts 
New Zealand white rabbits were anesthetized for 90 
seconds in a chamber containing CO2 gas, followed by 
cervical dislocation. The chest cavity was opened and the 
ventricles heparinized with a hypodermic syringe. The 
heart was attached to a Langendorff apparatus via the 
aorta to a Teflon cannula and then perfused for 5 minutes 
by retrograde aortic flow (2 ml/minute) using Krebs solu-
tion [118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.54 
mM NaHCO3, 1.2 mM MgSO4, 5.6 mM D(+) glucose, 5 
mM MOPS, 1.3 mM CaCl2, pH 7.0 at 37
oC] aerated for 
one hour with 95% O2/ 5% CO2. For hypoxic/acidotic 
conditions, the Langendorff perfused heart was initially 
treated for 5 minutes with the same Krebs solution aer-
ated with 95 % O2/ 5% CO2 followed by a 5 minute per-
fusion with the Krebs solution aerated with 100% CO2. 
During hypoxia/acidotic perfusion, we determined the pH 
of the cardiac tissue to be 5.6, which was similar to the 
pH of ischemic cardiac tissue reported by others [21]. 
The excised rabbit ventricles were homogenized in 4 
vols of 50 mM potassium phosphate buffer, pH 7.0, 
for 20 sec at 5
oC in a Waring blender fitted with a 30 
ml stainless steel cup. Then 100 µl samples of the 
crude rabbit heart homogenate were placed into 2 ml 
tubes for analysis. 
Langendorff perfusion of rat hearts 
Hearts were excised from anaesthetized male Sprague-
Dawley rats (350-400g) and mounted in a Langendorff 
perfusion system. Retrograde perfusion via the aorta was 
initiated at 37
oC at a constant flow of 9 mL min
-1 with 
oxygenated Krebs-Henseleit buffer (25 mM NaHCO3, 
118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM 
NaH2PO4, 1.2 mM CaCl2, 11 mM glucose, BSA 1 mg 
mL
-1, pH 7.4). After each heart was suspended, a World 
Precision Instruments (Sarasota, FL) model # BLPR pres-
sure transducer was introduced into the left ventricle via 
the Mitral valve. Each heart was stabilized for 30 minutes 
by perfusing with buffer. Only hearts exhibiting at least 
80 mmHg left ventricular developed pressure and dis-
playing heart rates of at least 100 bpm were subsequently 
treated by recirculation of 170 mL of a 20µM sphingosine 
solution for 90 minutes. In selected experiments, the 
Krebs-Henseleit buffer was supplemented with fresh 
(same day) human platelets obtained from the San Diego 
Blood Bank added to a final concentration of 7 x 10
5 
platelets mL
-1. Control hearts were subjected to similar 
conditions without sphingosine or platelet addition. For 
all hearts, 1.2 mL aliquots of eluted samples were col-
lected 20 minutes into the stabilization period and then 
every ten minutes during treatment. 
High Performance Liquid Chromatography (HPLC) 
detection of sphingolipids 
Prior to HPLC separation and quantitative analysis, 
sphingolipids were extracted from the cell-conditioned 
culture media as follows: 300 µl samples were depro-
teinized by adding 800 µl of warmed (70°C) butanol, 
vortexing and incubating at 70°C while rocking. The 
sample was then placed in a sonicating water bath for 
10 minutes. Denatured protein and aqueous phase were 
separated from the butanol layer by centrifugation at 
15,300 x g. The upper butanol layer was transferred and 
saponified by the addition of 0.5 M KOH. Samples 
were vortexed and then incubated at 70°C for 10 min-
utes, sonicated again and then centrifuged at 15,300 x g 
for 3 minutes. The butanol layer was decanted and dried 
down using a Savant (Holbrook, NY) SpeedVac and 
then resuspended in methanol. The extracts were then 
derivatized with O-phthalaldehyde (OPA) (Molecular 
Probes, Eugene, OR) as described by Merrill [25]. 
The HPLC was performed essentially as described by 
Merrill [25] with modifications as described previously 
[13, 23]. In a limited number of experiments, electron 
impact mass spectrometry was performed on the sphin-
golipids eluted by HPLC. Scattergrams were obtained 
by the University of California, Riverside MS Facility 
and were confirmed as authentic SPH and S1P by com-
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Figure 1. Hypoxia and acidosis increase sphingosine 
content of Langendorff-perfused rabbit hearts. 
Rabbit hearts were perfused for 5 minutes un-
der either normoxic or hypoxic/acidotic condi-
tions as described in Methods. The ventricles 
were rapidly homogenized in cold buffer and 
processed for sphingolipid extraction and re-
verse-phase HPLC. (p < 0.001, Student’s T-
test; n = 18 normoxia, n = 11 hypoxia). 
paring the scatter grams we obtained to those published 
on the NIST national database. 
Quantification of TNFα in cell-conditioned culture 
media 
A rat TNFα-specific double-capture, high-sensitivity 
ELISA kit (BioSource, Camarillo, CA) was used for the 
determination of TNFα in the cell conditioned media. 
Metabolism of sphingolipids in blood 
Fresh human blood was obtained from the San Diego 
Blood Bank and collected in standard serum tubes con-
taining EDTA. Care was given to prevent hemolysis of 
the samples. 300 µL of blood were placed in screw-
capped tubes to which was added 10 µL of 2000 
dpm/pmol 
3H-SPH (New England Nuclear, Boston MA). 
Samples were then vortexed for 15 seconds, and stored at 
37°C in a 95% Air/5% CO2 incubator. Incubations were 
terminated at the indicated time points by the addition of 
800 µL of 1-butanol. The samples were briefly agitated in 
a bath sonicator and then placed in a 50-70°C rocking in-
cubator for 15 minutes. Samples were then vortexed for 
15 seconds, sonicated for 5 minutes, and centrifuged for 
10 minutes at maximum speed in a microfuge. The bu-
tanol layer from each was then transferred and dried 
down using the Savant SpeedVac Plus (Holbrook, NY). 
The samples were then reconstituted in 50 µL of metha-
nol and spotted on 20x20 TLC silica gel G plates (Anal-
tec, Inc., Newark, DE). The plates were developed in bu-
tanol:acetic acid:H2O (3:1:1) according to [23] with 
modifications. The plates were allowed to air dry and 
then stained with Ninhydrin to visualize and determine Rf 
values of standards spotted on the same silica plate. The 
plates were then monitored for tritium using a Molecular 
Dynamics (Sunnyvale, CA) Phosphor tritium screen and 
cassette and read on an 860 Storm Scanner (Molecular 
Dynamics, Sunnyvale, CA) and quantified using Im-
ageQuant software. All reported values are means ± stan-
dard error of the mean (sem). 
Results 
Hypoxia and acidosis increase cardiac sphingosine levels 
An initial experiment was designed to determine if 
SPH levels increased in ventricular tissue exposed to 
`hypoxia. Rabbit hearts were used in order to obtain 
enough ventricular mass for the sphingolipid extraction 
procedure. A protocol similar to that successfully used 
by others in the Langendorff model [24] was used in an 
attempt to recreate the hypoxic/acidotic conditions as-
sociated with post-MI ischemia, except that 100% CO2 
was utilized to achieve a more acidic internal pH typical 
of ischemia [21]. After 5 minutes of hypoxia/acidosis, 
the ventricles were excised, homogenized and rapidly 
processed for sphingolipid extraction and HPLC. In the 
control crude homogenate shown in Figure 1, the con-
tent of SPH was 2.11 ± 0.27 nmol/gm and increased 
significantly (p < 0.0001, Student’s T-test) 13-fold to 
27.47 ± 3.98 nmol/gm in hypoxic/acidotic conditions. 
Hypoxia-triggered apoptosis 
The time courses of hypoxia-induced apoptosis and ne-
crosis in adult cardiomyocytes are shown in Figure 2 and 
demonstrate that at 5 hours of incubation, there was no 
appreciable cell death; however by 7 hours of hypoxia, 
significant (~26% or 3.7-fold increase, p < 0.001) apop-
tosis was evident compared to the normoxic condition. 
By 12 hours of hypoxia treatment, significant increases in 
both apoptosis (p < 0.006) and necrosis (p < 0.001) were 
evident. Many of these cells showed signs of both apop-
tosis and necrosis. In the absence of tissue macrophages 
that would otherwise engulf them, many apoptotic cells 
showed loss of membrane integrity as a sign of secondary 
necrosis. Control cultures of adult rat cardiomyocytes 
stained with H/PI demonstrated the typical rod-shaped 
appearance, crisp myofibril striations and blue-stained 
elongated nuclei characteristic of healthy cells. 
Adult cardiomyocytes released TNFα as a conse-
quence of both the 5 and 7 hour hypoxia treatments. 
For example during the 7 hours of normoxia, the con-
trol (normoxic) adult cardiomyocytes released 810 pg 
TNFα/10
6 cells (Table 1). Hypoxic cardiomyocytes 
released significantly (p < 0.001) more cytokine (8660 
pg TNFα/10
6 cells, 300 pg/mL, 17.9 nM) into the cell-
conditioned media (Table 1). 
Sphingosine is produced by hypoxic cardiomyocytes 
in culture 
Table 1 indicates that the cardiomyocytes produced 
appreciable SPH in response to hypoxia. These selected 
experiments were designed to determine if SPH was the 
only sphingolipid released from non-permeabilized, hy-
poxic cells, adult cardiomyocytes were made hypoxic 
under conditions that ensured that nearly all of the cells 
(~98%) in the experiment were viable and not perme-
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abilized to ensure that any observed SPH release came 
from intact cells. For these experiments, the cultures 
were washed vigorously to remove H/PI staining red 
cells prior to treatment so that after 5 hours of normoxia 
and hypoxia, only 1.44 ± .19% and 1.83 ± .15% (n 
TNFα and Sphingolipid Signaling in Cardiac Hypoxia 
= 26) permeabilized cells remained in the culture 
dishes, respectively (Table 1). Importantly, appreciable 
SPH (20.8 ± 2.7 fold increase, p < .001) was released 
before an appreciable increase in permeabilization had 
taken place. The amount of SPH released from the 5-
hour normoxic cells increased from 189 ± 24 to 3904 ± 
624 pmol/10
6 cells after hypoxic treatment. Comparable 
results were obtained from 7 hr incubations (Table 1). 
 
Figure 2. Hypoxia-induced cell death in adult cardio-
myocytes. Adult rat cardiomyocytes were cul-
tured under hypoxic conditions for the indicated 
times. Cell death by apoptosis was determined by 
the comet assay (panel A) and necrosis was de-
termined by H/PI (panel B). ANOVA analysis de-
termined that hypoxia produced significant (P < 
0.01) time-dependent increase in the percent 
apoptotic (A) and necrotic (B) dead cells (n = 3). 
Figure 3A shows typical chromatograms of the cell-
conditioned media from both control (normoxic) and 
hypoxic (95% N2, 5% CO2) adult cardiomyocytes. The 
only sphingolipid base that accumulated was sphingos-
ine (SPH). Figure 3B shows cumulative data from sev-
eral experiments and demonstrates that hypoxia resulted 
in the production of substantial amounts of SPH. Impor-
tantly, this figure shows that the significant (p < 0.0001) 
increase in total cell SPH was not reflected in an in-
creased intracellular content, but that nearly all (> 98%) 
of the SPH produced by hypoxia had been released 
from the cells into the cell-conditioned media. In addi-
tion, the lack of appreciable S1P in cardiomyocytes 
suggests that these cells lack appreciable sphingosine 
kinase required to convert SPH to intracellular S1P. 
Figure 4 shows the amount of SPH and TNFα (inset) 
released into the cell-conditioned media and expressed in 
terms of fold increases associated with hypoxia. These 
data demonstrate that the SPH response (~20-fold in-
crease over normoxia) was more profound than the TNFα 
response (~10-fold increase over normoxia, inset). Fur-
ther, Figure 4 shows that 30 min pretreatment with both 
the TNFRII:Fc receptor fragment designed to bind free 
TNFα, and the sphingomyelinase inhibitor, L-carnitine, 
were capable of significantly (p < 0.01) reducing the 
amount of released SPH by hypoxic cardiomyocytes. 
Released sphingosine is converted to sphingosine-1-
phosphate 
Rat hearts were excised and perfused with Krebs 
buffer containing 20 µM SPH (Figure 5). As expected, 
SPH appeared in the eluate of the hearts. Importantly, 
none of the Langendorff-perfused hearts demonstrated 
the presence of appreciable S1P (detection limit is 5 
pmol) or other sphingolipids. Figure 5 Panel C shows 
that a strikingly different result was obtained when 
fresh blood platelets (see 7 x 10
5 cells/mL) were added 
to the perfusate (see Methods). In the presence of plate-
lets, the SPH treated hearts demonstrated appreciable 
S1P production by 20 minutes as evidenced by the ap-
pearance of a very strong S1P peak at its retention time 
(~16 minutes). By 90 minutes of perfusion, almost all of 
the SPH had been converted to S1P (Panel D). 
Table 1 
Time of incubation   5 hrs   5 hrs   7 hrs   7 hrs 
Adult cardiomyocytes  Normoxia  Hypoxia  Normoxia Hypoxia 
% Permeabilized  1.44 ± .19  *1.83 ± .15  1.45 ± .15  *2.11 ± .18 
(necrotic)  cells  (n=26) (n=26) (n=24) (n=30) 
TNFα  572 ± 25  *7662 ± 1985  810 ± 155  *8660 ± 3150 
(pg/10
6  cells)  (n=3) (n=6) (n=9) (n=7) 
SPH  189 ± 24  *3940 ± 624  238 ± 39  *3860 ± 547
(pmol/10
6 cells)  (n=25)  (n=24)  (n=4)  (n=6) 
Values are means ± sem for the indicated number of independent experiments 
* Significant from control (respective normoxia) at the p<0.05 level or greater 
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Figure 4. TNFRII:Fc blocks SPH release. Cumulative data 
from adult cardiomyocytes treated with hypoxic con-
ditions for 5 hours were compared to normoxic cells 
also incubated for 5 hours. The fold-increases in 
SPH and TNFα (inset) in response to hypoxia are 
shown. Cells were pretreated for 30 min with 
TNFRII:Fc (0.5 ng/mL) prior to hypoxia (n = 19). 
 
Figure 3. Sphingosine is released from hypoxic cardio-
myocytes. Adult cardiomyocytes were cultured un-
der either normoxia or hypoxia conditions for 5 
hours. The cell-conditioned Tyrode’s solution was 
collected and the cells were scraped from the cul-
ture dish. Both cellular and extracellular sphingol-
ipids were extracted (see Methods) and then quan-
tified by reverse-phase HPLC (panel A). The reten-
tion times of the key sphingolipids (SPH, SPC, 
S1P, DHSPH) followed in these experiments are 
shown in panel A. Hypoxia resulted in a substan-
tial increase in a peak corresponding to D-
erythrosphingosine (SPH). Panel B shows the cu-
mulative data from 5 separate experiments in 
which the intracellular and extracellular (released) 
SPH was determined for hypoxic adult cardiomyo-
cytes. Hypoxia resulted in a significant (p < 0.001) 
increase in released SPH (n = 19). Over 98% of 
the total SPH produced by hypoxic cells were re-
leased into the culture media. For these cultures, 
only 2.1 ± 0.2% cells were necrotic (i.e., permeabi-
lized) as a consequence of 5 hours of hypoxia. 
In related experiments, uncoagulated whole blood sam-
ples were incubated in vitro for up to 48 hours with 
3H-
SPH and followed by TLC to evaluate the potential con-
version of radiolabeled SPH (Figure 6A). The major me-
tabolite that was appreciably labeled was sphingosine-1-
phosphate (S1P), presumably by the very active 
sphingosine kinase in blood [26]. Figure 6B shows 
cumulative data from several experiments and indicates 
that the conversion of 
3H-SPH to 
3H-S1P occurred within 
30 minutes and was stable in whole blood for the 15-hour 
time course of the experiment shown in Figure 5B. Only 
after several hours was it evident that a small amount of 
hexadecanal (HD) was produced by the low level of lyase 
enzyme present in blood platelets capable of converting 
S1P to hexadecanal and ethanolamine phosphate [2
Discussion 
We report here for the first time that cultured cardio-
myocytes subjected to hypoxia produce and, importantly, 
release into the extracellular environment significant 
quantities of SPH and the pro-inflammatory cytokine, 
TNFα. The TNFα concentration found in the cell-
conditioned media (300 pg/mL, 17.6 nM) exceeds the 
amount needed to produce its reported negative inotropic 
effects [4-6] and pro-apoptotic effects [11], even though 
the cytokine was diluted by the cell culture media to a far 
greater extent than one would expect in situ. SPH also 
produces negative inotropic and pro-apoptotic cardiac 
effects [28]. Hypoxia-triggered SPH release is at least in 
part dependent upon TNFα, since TNFRII:Fc was able to 
substantially block the effect. During hypoxia, TNFα is 
likely released before SPH and acts in an autocrine or 
paracrine manner on TNFα receptors expressed by rat 
cardiomyocytes [4] to activate sphingomyelinase. Figure 
6 shows a hypothetical model of these events. 
TNFα triggers cell death in heart cells [11, 27], and 
anti-TNFα antibodies reduce infarct size in a rabbit 
coronary occlusion model [28]. However, these data are 
in apparent conflict with a recent paper showing in-
creased apoptosis in a double TNFRI/RII receptor 
knock out mouse in the early (3 hrs) but not later post-
MI periods [29]. Explanations for the paradoxical ac-
tions of TNFα have been recently reviewed [30] and 
include both time and concentration dependent effects 
of the cytokine on the heart, as well as the fact that 
TNFα activates multiple signaling pathways. 
6]. 
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Figure 6. Sphingosine is rapidly converted to sphingos-
ine-1-phosphate by whole blood. Fresh human 
whole blood samples were incubated with 
3H-SPH 
for the indicated time periods, followed by butanol 
extraction and chromatographic separation by 
TLC (A). This solvent system is capable of sepa-
rating the major sphingolipids by their Rf values: 
sphingosylphosphoryl choline (SPC) sphigosine-
1-phosphate (S1P), dimethylsphingosine (DMS), 
D-erythrosphingosine (SPH), ceramide (CER) and 
hexadecanal (HD). The autoradiogram shows the 
conversion of SPH into S1P. Panel B shows the 
results of 5 separate experiments like the one 
shown in (A). Over the 15 hour (900 minute) time 
period of the experiment, S1P was nearly the only 
sphingolipid that was tritium labeled. 
 
Figure 5. Sphingosine-treated rat hearts do not produce 
S1P. Excised rat hearts were perfused with SPH (20 
µM) to determine if any cardiac cellular compo-
nents were capable of metabolizing SPH. Shown in 
Panels A+B are typical HPLC chromatograms of 
the eluate produced by a rat heart perfused for 2 
min and 90 min, respectively, with Krebs-Henseleit 
buffer showing only SPH in the eluate even after 90 
min of treatment. Panels C + D show an experiment 
in which the heart was perfused for 20 min and 90 
min, respectively, with Krebs-Henseleit containing 7 
x 10
5 purified human blood platelets. The gain on 
these chromatograms was purposefully increased 
so that in Panels A and B in particular, any S1P 
present in the eluate would be seen. 
Our finding that SPH is produced by hypoxic cardio-
myocytes is novel. Since SPH is rapidly formed from 
ceramide [34, 35], this is consistent with ceramide pro-
duction being one of the earliest responses to hypoxia 
and reoxygenation in cultured cardiomyocytes [14] and 
a 4.5-fold increase in ceramide content in hypoxic rat 
neonatal cardiomyocytes [31]. Sphingosine could be 
produced and released from the extracellular leaflet of 
the membrane where both sphingomyelin and sphingo-
myelinase are located [32]. 
From the 3860 pmol SPH released/10
6 cells demon-
strated in this study and assuming the adult human has a 
250-300 g heart and a 5 L blood volume, one can esti-TNFα and sphingolipid signaling in cardiac hypoxia 
mate that the hypoxic heart may release into the general 
circulation over ~400 pmol /ml SPH, exceeding the se-
rum SPH levels of healthy human volunteers (87 ± 5 
pmol/mL, n=8), in the range of SPH levels (~200 
pmol/mL) experienced by patients experiencing ische-
mia [23] but less than recently reported serum SPH lev-
els of 1,200 pmol/mL in rats subjected to monocro-
taline-induced heart failure [13]. The local concentra-
tion of SPH in the coronary circulation and cardiac in-
terstitium could be much higher, sufficiently high to 
reach the micromolar levels of SPH that produce cardio-
toxic and negative inotropic effects. Recently Heusch 
has demonstrated that canine hearts made ischemic by 
microembolization showed significant increases in myo-
cardial tissue levels of both TNFα and SPH [15]. Our 
findings that both mediators are ‘released’ from 
ischemic cardiomyocytes suggests that measuring tissue 
levels may dramatically underestimate the amount of 
TNFα and SPH produced by the ischemic myocardium. 
 
Figure 7. The central role of TNFα and sphingolipids in 
calcium deregulation and apoptosis in response to 
hypoxia. It is hypothesized that one of the earliest 
responses to hypoxia is the enzymatic processing 
or “shedding” of membrane-bound TNFα (pro-
TNF) by the action of metalomatrix proteases 
(also known as TACE, or TNFα Converting En-
zyme) located in the extracellular matrix of the 
cardiomyocyte. The TNFα that is released from 
the cardiomyocyte then acts in an autocrine or 
paracrine fashion on cardiomyocyte complement 
of TNFα receptors (TNFRI) that, in turn, activate 
the sphingomyelin signal transduction system. The 
principal signaling molecule produced by the 
TNFα trigger is SPH, the majority of which 
crosses the sarcolemma membrane and is re-
leased into the extracellular fluid compartment. 
Blood platelets and other blood components that 
possess sphingosine kinase (SPHK) convert SPH 
to sphingosine-1-phopshate, S1P. Igarashi and 
co-workers have shown that S1P is released from 
platelets and can partition into the serum [24]. 
Extracellular S1P is then free to act on the car-
diomyocyte complement of Edg receptors (EdgR) 
to exert its negative inotropic and cardiotoxic ef-
fects associated with calcium deregulation. SPH 
and S1P may also contribute to platelet activation 
and thrombus formation, thus complicating the 
ischemic episode. Cardiomyocyte-derived TNFα 
and SPH can be considered extracellular signal-
ing molecules that, in conjunction with S1P, can 
also signal fibroblasts and endothelial cells (not 
shown) to undergo post-MI remodeling and an-
giogenesis, respectively. 
Figure 5 demonstrates that rat hearts perfused with 
SPH are not capable of metabolizing it to S1P or other 
sphingolipids, suggesting that the SPH released from 
the cardiomyocytes needs to move from the interstitial 
space into the blood in order to be converted to S1P, 
presumably by blood components such as platelets [26]. 
Thus, it is likely that SPH does not have a chance to ac-
cumulate once it has contact with the blood and is in-
stead converted to its bioactive metabolite, S1P. The 
intercellular transfer of SPH between co-cultured CTLL 
and A31 cells has been demonstrated by others [33]. 
The protective action afforded by platelets “sponging” 
SPH and converting it to S1P may have only temporary 
advantages, however. If the S1P half-life in platelets is 
relatively long-lived, then platelet activation as at a 
thrombus would release high local concentrations of 
S1P that could have other untoward effects. 
S1P has only recently been appreciated as an extracel-
lular mediator that may contribute to cardiovascular dis-
ease [3, 34]. For example, S1P produces arrhythmias 
and coronary vasoconstriction [35, 36]. Extracellular 
S1P may also contribute to the negative inotropic state 
associated with ischemia. We have recently reported 
that cardiomyocytes express novel G protein-coupled 
receptors belonging to the Edg family and that Edg-1 
mediates S1P’s ability to cause a form of calcium de-
regulation characterized by increased diastolic calcium 
(i.e., calcium overload) and reduced systolic calcium 
(i.e., negative inotropism) [37], similar to the calcium 
responses exhibited by the ischemic myocardium [38, 
39]. Thus, if released from platelets, S1P could contrib-
ute to the negative inotropic effects of TNFα. More-
over, S1P may be a potent activator of intravascular 
thrombus [26, 40], providing a possible positive feed-
back loop to exacerbate coronary ischemia. 
Even though S1P at levels higher than 10 µM cause 
cell death in neonatal myocytes [41], low S1P levels can 
actually protect from hypoxic injury [41] and stimulate 
cardiomyocyte hypertrophy [42]. In addition, we specu-
late that S1P may act as an extracellular signaling mole-
cule to participate in post-MI remodeling events such as 
fibroblast proliferation and collagen gene expression 
and the resulting scar formation. In support of this post-
MI remodeling role is the recent finding that S1P is a 
very potent stimulator of angiogenesis [43]. In our labo-
ratory, S1P stimulates cardiac fibroblast proliferation 
and collagen I gene expression (unpublished observa-
tions). One may consider that all three mediators, 
TNFα, SPH and S1P, act as extracellular signals for 
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acute effects and that TNFα and S1P also contribute to 
compensatory and remodeling events. 
In sum, the current study demonstrates that hypoxia 
generates not only TNFα but also extracellular SPH, the 
majority of which can be converted to S1P by platelets. 
This study is the first to provide evidence that TNFα-
derived sphingolipid mediators are derived from hy-
poxic cardiomyocytes themselves. These mediators are 
important extracellular signaling molecules that partici-
pate in the pathology of cardiac ischemia. 
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